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ABSTRACT
Objective To predict antibiotic use after initial treatment 
with ibuprofen using data from a randomised controlled 
trial comparing ibuprofen to pivmecillinam in the treatment 
of women with symptoms of an uncomplicated urinary 
tract infection (UTI).
Setting 16 sites in a primary care setting in Norway, 
Sweden and Denmark.
Participants Data from 181 non- pregnant women aged 
18–60 presenting with symptoms of uncomplicated UTI, 
initially treated with ibuprofen.
Methods Using the least absolute shrinkage and selection 
operator logistic regression model, we conducted analyses 
to see if baseline information could help us predict 
which women could be treated with ibuprofen without 
risking treatment failure and which women should be 
recommended antibiotics.
Results Of the 143 women included in the final analysis, 
77 (53.8%) recovered without antibiotics and 66 (46.2 
%) were subsequently prescribed antibiotics. In the 
unadjusted binary logistic regression, the number of days 
with symptoms before inclusion (<3 days) and feeling 
moderately unwell or worse (≥4 on a scale of 0–6) were 
significant predictors for subsequent antibiotic use. In the 
adjusted model, no predictors were significantly associated 
with subsequent antibiotic use. The area under the curve 
of the final model was 0.66 (95% CI: 0.57 to 0.74).
Conclusion We did not find any baseline information 
that significantly predicted the use of antibiotic treatment. 
Identifying women who need antibiotic treatment to 
manage their uncomplicated UTI is still challenging. Larger 
data sets are needed to develop models that are more 
accurate.
Trial registration number  ClinicalTrials. gov 
(NCT01849926).
INTRODUCTION
With years of research and clinical experi-
ence, the diagnosis and treatment of uncom-
plicated urinary tract infections (UTIs) still 
poses a challenge for clinicians. A positive 
urine culture has been considered the defi-
nition of a ‘true’ UTI, but many women with 
symptoms of a UTI have negative cultures 
and still benefit from antibiotic treatment.1 
Placebo studies have shown that women with 
a positive urine culture become symptom free 
without antibiotic treatment.2
Antibiotic resistance is on the rise, and 
for the last three decades, researchers have 
sought to find ways of reducing unnecessary 
use of antibiotics. The potential for reducing 
antibiotic use is the largest in self- limiting 
conditions, such as respiratory tract infec-
tions and uncomplicated UTIs, the two most 
common reasons for prescribing antibiotics 
in general practice.3 The focus has shifted 
from finding the easiest way to diagnose 
and treat a UTI to identifying the patients 
who actually need antibiotics to recover, and 
which patients can be recommended a wait- 
and- see strategy. Both placebo trials and trials 
comparing non- steroidal anti- inflammatory 
drugs (NSAIDs) to antibiotics have proven 
Strengths and limitations of this study
 ► This study aims to predict the use of antibiotics after 
initial symptomatic treatment in women with symp-
toms of an uncomplicated urinary tract infection us-
ing clinical cure as the main outcome.
 ► The data are obtained from a relatively large ran-
domised controlled trial conducted in an unselected 
population of women in primary care.
 ► The study population was the subgroup of patients 
receiving ibuprofen, 143/181 (79%) had complete 
baseline data and were included in the analyses.
 ► This population might not be large enough to avoid 
type II error, as the trial was not adequately powered 
to perform predictor analysis.
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that antibiotic treatment is superior with regards to 
clinical and bacteriological cures, but they have also 
shown that a substantial part of the patients do recover 
without antibiotic treatment, regardless of urine culture 
results.4–8 In 2010, Little et al compared the effectiveness 
of five different approaches in the management of UTIs, 
they concluded that antibiotics targeted with dipstick 
tests with a delayed prescription as backup or empirical 
delayed prescription could help reduce antibiotic use.9 
The ATAFUTI Trial (Alternative Treatments of Adult 
Female Urinary Tract Infection: a double blind, placebo 
controlled, factorial randomised trial of Uva ursi and 
open pragmatic trial of ibuprofen) published in 2019 
concluded that ibuprofen reduced antibiotic consump-
tion without increasing complications.10
The trial by Gagyor et al comparing ibuprofen to fosfo-
mycin in the treatment of uncomplicated UTI showed 
that two- thirds of the women recovered without antibiotic 
treatment.6
We conducted a randomised controlled trial comparing 
ibuprofen to pivmecillinam in the treatment of uncom-
plicated UTIs, the IMUTI Trial (Ibuprofen versus pivMe-
cillinam for uncomplicated Urinary Tract Infection in 
women).8 We found that 53% of the women initially 
treated with ibuprofen recovered without using antibi-
otics, but pivmecillinam was significantly more efficient 
than ibuprofen in achieving both clinical and bacterio-
logical cures.
Gagyor et al used data from their trial to develop a 
prediction model for which women should be recom-
mended immediate antibiotic treatment and who could 
be recommended initial treatment with ibuprofen.11 This 
was the first prediction model made with clinical cure as 
the reference standard, as opposed to previous studies 
aiming to predict which patients will have a positive urine 
culture.12–19 Gagyor et al identified five factors predicting 
the use of subsequent antibiotic treatment in the group 
initially treated with ibuprofen: a positive test result for 
nitrite, leucocytes, and erythrocytes, moderate- to- severe 
urinary urgency or frequency, and impairment of regular 
daily activities most of the time. Their model was moder-
ately accurate (area under the curve (AUC)=0.73 (95% 
CI: 0.67 to 0.80)), and they concluded that in order to 
construct a prediction model that is adequate for general 
practice, more studies from various independent samples 
are needed. Hence, we aimed to analyse the baseline 
information from our trial to identify
 ► which women could be treated with ibuprofen without 
risk of therapeutic failure and
 ► which women should be recommended antibiotics.
METHODS
Context and study design
The analyses in this manuscript are based on data from 
the IMUTI Trial comparing ibuprofen with pivmecil-
linam in the treatment of uncomplicated UTI. The trial 
aimed at comparing effectiveness of the two treatment 
regimens with clinical cure by day 4 as the main outcome 
measure. Women were instructed to consult the study site 
or their local general practitioner’s (GP’s) office/out- of- 
hours (OOH) service if they did not recover or if they 
experienced worsening of symptoms/complications. On 
reconsultation, they were treated according to the study 
protocol or at the discretion of the GP when reconsulting 
outside of the study site.
Median time until the patients felt well was 6 days in the 
ibuprofen group and 3 days in the pivmecillinam group. 
In the ibuprofen group, 47% of the patients received 
subsequent antibiotic treatment within 4 weeks versus 
11% in the pivmecillinam group.
We performed analyses on data from the ibuprofen 
group to identify which measures and clinical findings 
presented at baseline were associated with the use of 
subsequent antibiotic treatment.
Patient and public involvement
No patients were involved in the design, conduct, 
reporting or dissemination of our research.
Participants
Non- pregnant women, age 18–60, presenting to the 
GP or an OOH service with symptoms of an uncompli-
cated UTI were enrolled in the study. Inclusion criteria 
were dysuria combined with either increased urinary 
frequency or urinary urgency or both, with or without 
visible haematuria.
The main exclusion criteria were: duration of symptoms 
for more than 7 days, any sign of an upper UTI (fever and 
upper back pain), vaginal discharge, severe abdominal 
pain, conditions that could potentially lead to complica-
tions (such as diabetes, kidney disease, severe gastritis and 
previous pyelonephritis), symptoms of a UTI within the 
last 4 weeks, or use of antibiotics within the last 2 weeks.
Development of the prediction model
To develop a helpful clinical decision aid, we decided to 
include only predictors present at baseline.
Self- reported symptom burden at inclusion was regis-
tered in a patient diary and included dysuria, increased 
urinary frequency and urgency, visible haematuria, fever, 
abdominal pain when not passing urine and feeling 
unwell. Each symptom was graded on a scale from 0 to 6, 
where 0 was ‘normal/not affected’ and 6 was ‘as bad as it 
could be’, fever (>38°C) and visible haematuria were yes/
no questions. For the analyses in this article, we decided 
to use the three symptoms represented in the inclusion 
criteria as individual predictors: dysuria, increased urinary 
frequency and urinary urgency. We also decided to use 
‘feeling unwell’ and ‘abdominal pain when not passing 
urine’ as separate predictors. Self- reported fever was not 
used since all patients had their temperature measured 
at inclusion, and it had to be lower than 38°C for inclu-
sion in the study. Visible haematuria was not included as 
an independent predictor as we considered the dipstick 
result for haematuria to be a more sensitive and accurate 
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predictor. Urine culture was not included in the analysis 
since the results are not available at presentation.
We ended up with five factors of interest: (1) age, (2) 
number of days with symptoms before inclusion, (3) 
number of UTIs treated with antibiotics within the last 
year, (4) self- reported symptom burden at inclusion 
and (5) urinary dipstick results (leukocytes, nitrite and 
blood/erythrocytes).
Statistical analysis
We performed univariate and multivariate logistic regres-
sion analysis. The predictors were purposefully selected 
using a cut- off of p≤0.20 from the unadjusted analysis. 
Age was included in the adjusted model as an essential 
predictor. We used the least absolute shrinkage and selec-
tion operator (LASSO) logistic regression model to create 
a parsimonious model by selecting a subset of predictors 
and shrinking the rest to zero.20
The LASSO logistic model selected candidate predic-
tors for subsequent need of antibiotics. Using the esti-
mated regression coefficients (β) of the final model, 
conditional predicted probabilities for the subsequent 
use of antibiotics were estimated as the exponent of each 
woman’s risk score (see online supplementary file 1 for 
details). The predicted probabilities were estimated for 
each woman with no missing data points in the selected 
predictors.
To assess the accuracy of the final fitted prediction 
model, we plotted sensitivity of the test against (1−spec-
ificity) to produce the area under the receiver operating 
characteristic (ROC) curve. The area under the ROC 
curve with 95% CI was calculated and used to assess how 
well the model discriminated between the women who 
would subsequently need antibiotics from those who did 
not. If the area under the ROC is equal to 1, then the 
model perfectly discriminates group 0 from group 1, 
whereas a value of 0.5 suggests no discrimination.
Several cut- off points of estimated risk scores were 
used to estimate sensitivity, specificity, the proportion of 
women that the model predicted would be recommended 
for antibiotics by their GPs relative to all women and the 
proportion of women that the model predicted would 
return to the practices due to treatment failure. We used 
bootstrap resampling to determine the accuracy of our 
sample estimates. The LASSO logistic regression model 
was fitted using the glmnet and pROC packages in R.21
RESULTS
In total, 143 women with UTI in the ibuprofen group 
were included in the analysis (figure 1). Of these, 77 
(53.8%) recovered without antibiotics and 66 (46.2 %) 
were given subsequent antibiotic treatment. The base-
line characteristics of these patients are presented in 
table 1. The women who subsequently used antibiotics 
had a higher rate of positive urine dipstick findings, had 
a greater burden of some symptoms and had experienced 
symptoms for fewer days compared with the women who 
recovered without antibiotics.
Standard logistic regression
In the unadjusted binary logistic regression (table 1), the 
number of days with symptoms before inclusion (<3 days) 
and feeling unwell (≥4 on a scale of 0–6) were significant 
predictors for the subsequent use of antibiotic treatment. 
However, in a backward stepwise logistic regression (data 
not shown), only the number of days with symptoms was 
significantly associated with the use of antibiotics. At the 
5% significance level, we did not find statistically signifi-
cant predictors that were associated with the use of antibi-
otics in the adjusted model, presented in table 1.
LASSO logistic regression model
In the LASSO logistic regression model presented in 
table 2, the following predictors were selected: days with 
symptoms (<3/≥3), urine dipstick blood (negative/posi-
tive) and feeling unwell (<4/≥4). Patient age (<26/≥26 
years) was forced into the model as a clinically rele-
vant variable. We also explored the potential benefit of 
including two- way interaction terms. Their inclusion did 
not influence the predictive ability of the final model; 
hence, they were not considered. For a given woman, the 
regression coefficient estimates of the selected predic-
tors were used to compute her predicted probability 
Figure 1 Flow of participants.
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of receiving an antibiotic later on. Online supplemen-
tary file 1 shows how these predicted probabilities were 
computed. For example, a woman presenting with symp-
toms for less than 3 days before inclusion, feeling worse 
than moderately unwell (graded ≥4 on a scale from 0 
to 6) at inclusion and with a positive urine dipstick for 
blood, had a 55.7% chance of needing antibiotics later 
on compared with a 49.3% predicted probability if she 
had had symptoms for 3 days or more prior to inclusion.
The performance of the model in differentiating 
women who would subsequently use antibiotics from 
those who would not is shown in the area under the 
ROC curve in figure 2, with an AUC of 0.66 (95% CI: 
0.57 to 0.74).
Table 3 shows the accuracy of prediction for different 
risk score cut- off points. The risk score that maximised 
sensitivity and specificity was 0.45, with sensitivity of 
75.8% (95% CI: 63.6 to 85.5) and specificity of 43.6% 
(95% CI: 32.4 to 55.3). A sensitivity of 75.8% implies that 
75.8% of the women presenting with UTI were correctly 
recommended antibiotics, whereas a specificity of 43.6% 
means that 43.6% of the women, not recommended anti-
biotics, were able to manage their condition without anti-
biotics. At this risk score (>0.45), 65.3% of all the women 
Table 1 Predictors for subsequent antibiotic treatment in the ibuprofen group—standard logistic regression model
No antibiotics (%) Antibiotics (%) Unadjusted *Adjusted
n=77 n=66 OR (95% CI) P value OR (95% CI) P value
Age (ref: <26 years)
  ≥26 36 (46.8) 35 (53.0) 1.29 (0.67 to 2.48) 0.46 1.31 (0.66 to 2.60) 0.45
Days with symptoms (ref: ≥3)
  <3 44 (57.1) 49 (74.2) 2.16 (1.06 to 4.41) 0.03 1.83 (0.86 to 3.88) 0.12
Urine dipstick leukocytes (ref: negative)
  Positive 69 (89.6) 63 (95.5) 2.43 (0.62 to 9.58) 0.20 1.50 (0.31 to 7.26) 0.61
Urine dipstick blood (ref: negative)
  Positive 55 (71.4) 55 (83.3) 2.00 (0.89 to 4.52) 0.10 1.54 (0.59 to 4.05) 0.38
Feeling unwell (ref: <4)
  ≥4 23 (28.6) 30 (45.5) 2.08 (1.04 to 4.16) 0.04 1.88 (0.91 to 3.86) 0.09
Urine dipstick nitrate (ref: negative)
  Positive 12 (15.6) 15 (22.7) 1.59 (0.69 to 3.70) 0.28     
Dysuria (ref: <4)
  ≥4 51 (66.2) 45 (68.2) 1.09 (0.54 to 2.20) 0.81     
Urinary urgency (ref: <4)
  ≥4 60 (77.9) 51 (77.3) 0.96 (0.44 to 2.12) 0.93     
Urinary frequency (ref: <4)
  ≥4 57 (74.0) 47 (71.2) 0.87 (0.42 to 1.81) 0.71     
Antibiotic treatments last year (ref: <3)
  ≥3 6 (7.8) 8 (12.1) 1.63 (0.54 to 4.97) 0.39     
Abdominal pain (ref: <4)
  ≥4 13 (16.9) 14 (21.2) 1.32 (0.57 to 3.07) 0.51     
*Adjusted model based on predictors with p≤0.20 in the unadjusted analysis. Age was included as an essential variable.
Table 2 Estimates of regression coefficients, obtained from 
the penalised method, LASSO
Predictors Selected
Logistic regression 
coefficient estimates, 
LASSO (risk score)
Intercept – −0.64
Days with symptoms <3 Yes 0.26
Urine dipstick blood 
positive
Yes 0.15
Feeling unwell (≥4) Yes 0.21
Age ≥26 No 0.22
Urine dipstick 
leukocytes
No
Urine dipstick nitrite No
Dysuria No
Urinary urgency No
Urinary frequency No
Antibiotic treatments 
last year
No
Abdominal pain No
LASSO, least absolute shrinkage and selection operator.
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presenting with UTI would be recommended antibiotics 
by the GP. However, treatment failure would be observed 
in 11.1% of all UTI cases forcing these women to return 
to the practices for treatment. A specificity of 43.6% also 
suggests that a large proportion of the women recom-
mended antibiotic treatment would have been able to 
handle their condition without antibiotics.
Complications
In our study population, 12 patients developed a febrile 
UTI/upper UTI (5/7). We had complete baseline data 
for 10 of these 12 patients. All 10 had a urine dipstick 
positive for blood (value ≥3) and leucocytes,1–3 but nitrite 
negative. The mean age was 29, 6/10 had had symptoms 
for less than 3 days before inclusion, 9/10 reported a 
symptom burden of ≥4 for urinary urgency, 8/10 reported 
urinary frequency ≥4, 5/10 reported feeling unwell ≥4, 
5/10 reported dysuria ≥4, only 1 reported abdominal pain 
≥4 and none had had more than 3 antibiotic treatments 
during the last 12 months. Six patients had a prediction 
score of >0.45 and four had a score of <0.45. This means 
that if the suggested prediction rule had been used/
followed, 60% would have accurately been prescribed 
antibiotics, whereas 40% would have been treated with 
ibuprofen and experienced complications.
DISCUSSION
Main results
In our unadjusted analysis, the number of days with symp-
toms (<3) and degree of feeling unwell were significantly 
associated with the use of antibiotics, but in further anal-
ysis, no single factor was associated with the use of antibi-
otics. A scoring system based on four relevant predictors 
resulted in an area under the ROC curve of 0.66 (95% CI: 
0.57 to 0.74).
We chose to dichotomise all continuous variables in 
the prediction model. This was a decision made after 
initially performing the analyses using continuous vari-
ables. Thereafter, we converted the continuous variables 
to categorical variables by grouping the values into two 
or three groups. There was little difference in the results. 
This led to the decision of dichotomising each contin-
uous variable for simplicity. For each variable, we kept the 
cut- off value that yielded the biggest difference. For the 
age variable this cut- off value was 26 years, the median age 
in our study population, which also made sense clinically. 
Dichotomising continuous variables has been warned 
against, since this simplification often comes at the cost 
of creating a prediction model with less statistical power.22 
Given the small difference in accuracy in our prediction 
model, we decided to use dichotomised variables in the 
final model.
Strengths and limitations
This is a relatively larger trial performed in an unselected 
population of women with presumably uncomplicated 
Figure 2 Receiver operating characteristic (ROC) curve 
for the performance of the least absolute shrinkage and 
selection operator risk score in identifying women who would 
subsequently use antibiotic treatment. The area under the 
ROC curve is 0.66 (0.57, 0.74).
Table 3 Sensitivity, specificity, predicted proportion of women who received antibiotics and the predicted proportion of 
women who would return to the practices due to treatment failure
Risk score 
cut- off point* Sensitivity, %, (95% CI) Specificity, %, (95% CI)
Antibiotics prescribed, 
%, (95% CI)
Returning patients, 
%, (95% CI)
>0.21 100.0 (94.6 to 100.0) 5.1 (1.4 to 12.6) 97.2 (93.0 to 99.2) –
>0.30 98.5 (91.8 to 100.0) 16.7 (9.2 to 26.8) 90.3 (84.2 to 94.6) 0.7 (0.0 to 3.8)
>0.39 75.8 (63.6 to 85.5) 42.9 (31.6 to 54.6) 65.3 (56.9 to 73.0) 11.1 (6.5 to 17.4)
>0.45 75.8 (63.6 to 85.5) 43.6 (32.4 to 55.3) 65.3 (56.9 to 73.0) 11.1 (6.5 to 17.4)
>0.48 53.0 (40.3 to 65.4) 64.1 (52.4 to 74.7) 43.8 (35.5 to 52.3) 21.5 (15.1 to 29.1)
>0.57 28.8 (18.3 to 41.3) 83.3 (73.2 to 90.8) 22.2 (15.7 to 29.9) 32.6 (25.1 to 40.9)
>0.65 15.2 (7.5 to 26.1) 91.0 (82.4 to 96.3) 11.8 (7.0 to 18.2) 38.9 (30.9 to 47.4)
Estimates are given with 95% CIs at different cut- off points.
*Based on the sum of the logistic regression coefficients for each predictor.
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UTI. However, our study was not adequately powered 
to perform predictor analyses. We only looked at the 
patients receiving ibuprofen who had complete baseline 
data. Starting with 181 patients, only 143 patients, 79%, 
had complete baseline data, this might not be a large 
enough population to avoid type II error. The estima-
tion of an appropriate sample size for clinical prediction 
models is challenging because one has to consider the 
sizes of the training set, cross- validation and the test set. 
However, there are different ways of calculating such a 
sample size, some approaches are described by Riley et 
al in a recent publication.23 Using the fact that we had 
11 baseline predictors and an estimated binary outcome 
of 0.4 (the proportion of patients who would come back 
for an antibiotic treatment), their method would give an 
estimated sample size of 604 patients. We ended up with 
only 4 predictors in our final model, if we include only 4 
predictors in the same calculation formula, a sample size 
of 369 patients is estimated.
Furthermore, our population was young compared 
with similar study populations,6 24 and a majority of the 
patients were from OOH services and may differ some-
what from an ordinary general practice population.
Comparison with other studies
Gagyor et al performed similar analyses to ours after their 
randomised trial.11 They developed a scoring system 
where using a relevant cut- off score for initiating antibi-
otic treatment would lead to 58% being treated with anti-
biotics and 42% with initial symptomatic treatment. This 
would still lead to some overprescribing, but only 6% of 
the women would come back for a second consultation 
potentially leading to an antibiotic prescription. Apart 
from a positive urine dipstick for erythrocytes and feeling 
unwell (similar to ‘impairment of regular daily activi-
ties’), our results did not confirm the predictors found in 
the Gagyor Study. We do not have a good explanation for 
this. The number of patients included in our analyses was 
smaller than the number of patients in the trial by Gagyor 
et al, this might make our results less reliable. The mean 
age in our trial population was lower than the mean age 
in the trial by Gagyor et al, this might also have lead to a 
difference in selection of predictors.
Identifying which patients will need antibiotics to 
treat their uncomplicated UTI and which patients can 
be recommended symptomatic relief is still challenging. 
Larger data sets are needed to develop more accurate 
prediction models eligible for use in primary care. An 
individual patient data (IPD) meta- analysis based on 
studies comparing placebo or NSAIDs to antibiotic treat-
ment could help achieve this. Merging data from different 
trials for analysis purposes are challenging. The baseline 
data will differ somewhat between the trials, the scales 
used to measure symptoms and the outcome measures 
might have some variations. However, we believe that an 
IPD meta- analysis could provide more information, and 
give us a large enough sample size to develop a more 
accurate prediction model. Such an analysis might also 
enable us to distinguish between subgroups in the study 
populations, for example younger versus older women, 
and possibly find different predictors in the different 
subgroups. Previous studies aiming to predict which 
patients would need antibiotic treatment to manage 
their UTI have used a positive urine culture as the gold 
standard for defining a UTI. Several studies have been 
conducted to find predictors for a positive urine culture 
among women presenting with symptoms of a UTI. They 
have reached an overall conclusion that, apart from clin-
ical symptoms, a urinary dipstick positive for nitrite and/
or leukocytes, or positive for leukocytes and blood, is the 
only predictor with a high positive predictive value.25–27 
However, the negative predictive values are relatively 
poor, hence using only the dipstick as a predictor will 
underestimate the need for antibiotic treatment. At the 
same time, it will overestimate the need for antibiotics, 
since several women with a positive urine culture will get 
well without antibiotic treatment.
Implications for practice
We were not able to find any baseline information that 
could significantly and accurately predict the need for 
subsequent antibiotic treatment. Our prediction model 
yielded an AUC of 0.66, and in clinical practice, it will not 
be of much help in identifying which patients should be 
treated with antibiotics. However, the 95% CI was above 
0.5, and thus the selected predictors can potentially indi-
cate the seriousness of the condition, a higher degree of 
feeling unwell, symptoms for less than 3 days combined 
with a positive urine dipstick for blood could indicate that 
initial treatment with ibuprofen will lead to treatment 
failure. This again indicates that patients experiencing 
milder symptoms could benefit from a wait- and- see 
strategy with initial symptomatic treatment.
Delayed prescribing has proven to reduce the use of 
antibiotics,9 and at least a third of women with symptoms 
of a UTI will be positive to such an approach.28 A system-
atic review conducted by Wawrysiuk et al concludes that 
using shared decision- making and delayed prescribing 
with advice to take NSAIDs for symptom relief can be a 
preferred strategy for patients with uncomplicated UTIs, 
but the patient should receive close follow- up.29 Given the 
current knowledge, recommending symptomatic relief to 
patients who are willing to delay taking antibiotics, with a 
backup prescription at hand, seems to be a safe and effi-
cient strategy to lower antibiotic prescribing for women 
with uncomplicated UTIs.
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